Table 1.
Baseline characteristics of patients with non‐small cell lung cancer according to tumor microenvironment subtypes (N = 52)
| Characteristics | Number of patients, n (%) | P value | |||
|---|---|---|---|---|---|
| Type 1 (n = 7, 13.5%) | Type 2 (n = 22, 42.3%) | Type 3 (n = 9, 17.3%) | Type 4 (n = 14, 26.9%) | ||
| Age, years; median (range) | 67 (38‐88) | 71 (50‐82) | 71 (48‐77) | 74.5 (65‐81) | .1500 |
| <70 | 4 (57.1) | 10 (45.5) | 4 (44.4) | 2 (14.3) | |
| ≥70 | 3 (42.9) | 12 (54.5) | 5 (55.6) | 12 (85.7) | |
| Sex | |||||
| Male | 2 (28.6) | 7 (31.8) | 4 (44.4) | 4 (28.6) | .9000 |
| Female | 5 (71.4) | 15 (68.2) | 5 (55.6) | 10 (71.4) | |
| Smoking | |||||
| Smoker | 1 (14.3) | 8 (36.4) | 3 (33.3) | 3 (21.4) | .6700 |
| Never smoker | 6 (85.7) | 14 (63.6) | 6 (66.7) | 11 (78.6) | |
| Stage | |||||
| III | 1 (14.3) | 3 (13.6) | 0 (0.0) | 1 (7.1) | .7700 |
| IV | 6 (85.7) | 19 (86.4) | 9 (100.0) | 13 (92.9) | |
| ECOG PS | |||||
| 0‐1 | 4 (57.1) | 19 (86.4) | 8 (88.9) | 13 (92.9) | .2300 |
| ≥2 | 3 (42.9) | 3 (13.6) | 1 (11.1) | 1 (7.1) | |
| EGFR mutation status | |||||
| Exon19 deletion | 1 (14.3) | 12 (54.5) | 6 (66.7) | 5 (35.7) | .1400 |
| Exon21 L858R | 6 (85.7) | 10 (45.5) | 3 (33.3) | 9 (64.3) | |
| PreT790M | |||||
| Positive | 4 (57.1) | 8 (36.4) | 7 (77.8) | 3 (21.4) | .0430 |
| Negative | 3 (42.9) | 14 (63.6) | 2 (22.2) | 11 (78.6) | |
| First‐line EGFR‐TKI | |||||
| Gefitinib | 4 (57.1) | 8 (36.4) | 3 (33.3) | 5 (35.7) | .5800 |
| Erlotinib | 2 (28.6) | 3 (13.6) | 3 (33.3) | 4 (28.6) | |
| Afatinib | 1 (14.3) | 1 (4.5) | 0 (0.0) | 0 (0.0) | |
| Gefitinib/erlotiniba | 0 (0.0) | 9 (40.9) | 3 (33.3) | 4 (28.6) | |
| Afatinib/gefitiniba | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | |
| Erlotinib/afatiniba | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (7.1) | |
| PD‐L2 expression | |||||
| Positive | 4 (57.1) | 1 (4.5) | 1 (11.1) | 1 (7.1) | .0090 |
| Negative | 3 (42.9) | 21 (95.5) | 8 (88.9) | 13 (92.9) | |
a
In this study, switch of epidermal growth factor receptor‐ tyrosine kinase inhibitor (EGFR‐TKI) due to an adverse event was considered as continuation of EGFR‐TKI therapy.
PD‐L2, programmed cell death‐1 ligand‐2; PreT790M, pretreatment T790M; PS, performance status; TME, tumor microenvironment; Type 1, PD‐L1 high/CD8+ tumor‐infiltrating lymphocyte (TIL) high; Type 2, PD‐L1 low/CD8+ TIL low; Type 3, PD‐L1 high/CD8+ TIL low; Type 4, PD‐L1 low/CD8+ TIL high.